Definium Therapeutics’ first Phase 3 study of LSD compound DT120 for generalised anxiety disorder met its primary and key secondary endpoints, prompting further analysis of the topline data.

The analysis examines DT120’s first Phase 3 readout for generalised anxiety disorder after the study met its primary and key secondary endpoints. Researchers highlighted 14% remission and 43% response rates after a single dose, and questioned whether additional dosing sessions could improve outcomes.